Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDELA-302: BGB-43395 plus letrozole vs CDK4/6 inhibitors plus letrozole in untreated advanced HR+/HER2- breast cancer
jRCT2031260300Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jun 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bgb-43395 in breast cancer (2 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-Free Survival by BICR. Started Jun 2026; status: recruiting.
02
Drugs
bgb-43395
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031260300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260300.